We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cotellic

News List

Roche gets US FDA approval for Tecentriq combo to treat advanced melanoma expresspharma
August 03, 2020
The approval is based on results from the Phase III IMspire150 study, in which the addition of Tecentriq to Cotellic and Zelboraf helped people live longer without disease worsening or death.
Roche’s Tecentriq/Cotellic study fails in colorectal cancer trial pharmatimes
July 09, 2018
Roche has revealed that a combination of Tecentriq and Cotellic tested in a late-stage trial failed to improve overall survival compared to regorafenib in patients with advanced metastatic colorectal cancer (CRC).
TECENTRIQ, COTELLIC Did Not Meet Primary Endpoint americanpharmaceuticalreview
May 18, 2018
Genentech announced the Phase III IMblaze370 study evaluating the combination of TECENTRIQ (atezolizumab) and COTELLIC (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib.